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Around 1980, I helped discover the new antiseizure drug, 
fosphenytoin.  It took almost 16 years for this drug to undergo clinical trials 
and to be approved by the FDA.  Because of our naiveté at the time, we 
did not file for worldwide patent protection.  Only patent protection in the 
United States was granted, and the compound was licensed to a company 
at a low royalty rate.  Also, the licensing agreement did not have milestone 
payments and a due diligence clause, which contributed to the delay in 
reaching the market place, i.e. the University could not place any pressure 
on the companies involved to “move things along."  Thus the health 
benefits to society were delayed and the financial benefits to the 
University were less than they could have been. 
 
The University of Kansas and other universities have become more 
savvy at technology transfer and licensing.  State and State/private 
economic development units such as KTEC (Kansas Technology 
Enterprise Corporation) have helped support applied research allowing 
promising university-based research concepts to be advanced to 
“commercial grade” quality.  Thus technologies can be moved beyond 
concept to potential commercial reality, increasing their value and 
hopefully the economic impact to the State.  Also, because of our past 
experiences, we have learned what our intellectual property is worth and 
have developed the expertise to negotiate more favorable agreements.   
 
We have helped launch three new companies over the last seven 
years.  The bases for the companies have been technologies developed in 
the Center for Drug Delivery Research at the Higuchi Biosciences Center.  
It is our hope that these three companies will prosper and contribute 
significantly to the Kansas economy by providing high paying, technology-
based jobs.  With each new company we launch, we become smarter at 
optimizing the return to the State and the University.  One of the goals of 
KTEC and the Centers of Excellence can be best defined by the cycle 
shown on the following page. 
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 To be successful, the University, and each of these companies, had 
to protect their intellectual property by filing patents in a timely manner.  
This leads to a bit of a dilemma, that can be described as “Publish AND 
Perish."  I would like to quote verbatim from an “Opinion” article I wrote in 
the Lawrence Journal World in 1993. 
 
 “Publish AND perish.  What heresy!  Traditionally, universities have 
existed to generate and disseminate knowledge. They encourage 
publication through the tenure, promotion and merit salary processes, in 
which quantity and quality of publications plays a major role; thus the 
often-quoted cliché "publish OR perish."  However, in some fields or areas 
of research there are occasional, valid reasons to delay publication of 
information on novel technologies until patents or copyrights can be filed. 
 
 The state, nation and society might be the losers if information 
about promising new technologies developed at universities is made 
public prior to receiving patent or copyright protection.  Unprotected 
technology is unlikely to ever be developed and used to the benefit of 
society.  It's a simple case of economics.  Let me explain by using 
examples in my own field, pharmaceutical sciences. 
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 To develop a new drug and obtain approval by the FDA, a company 
must invest a minimum of around $250-500 million, and the process takes 
8 to 12 years.  The drug must achieve annual sales of more than $250-
500 million/year over the five to nine years remaining in the 20-year patent 
life.  This allows the company to recoup its investment, continue its 
product line through research and development of other drug entities, and 
cover the cost of products that fail to reach the market.  In the unlikely 
event that a company were to take unprotected technology through the 
regulatory process to gain FDA approval, generic companies would be 
free to produce the product at a fraction of the cost and risk.  They would 
not have to spend the $250-500 million in R&D and regulatory costs.  The 
sponsoring company would not cover its costs and would lose any 
economic benefit even though they might be first with the technology. 
 
 It just does not make economic sense to invest in a new drug or 
technology unless a strong worldwide patent protects it.  As a result, few 
companies or investors will negotiate with inventors for rights to a new 
pharmaceutical technology if it is unprotected. 
 
 While patent protection is essential for commercialization, its real 
value lies in the fact that it enables development of a new drug or 
technology, which might save lives or enhance the quality of life.  The 
drug's therapeutic benefits might allow individuals to return to the work 
force, thus lowering health care costs and reducing the direct and indirect 
financial burden to society. Additionally, university-based research often 
focuses on cures and treatments for more obscure diseases that may not 
be big money makers but may be commercialized under the "orphan" drug 
act. 
 
 There are also financial benefits to the university and society for a 
protected technology.  First, the university is in a much stronger position to 
negotiate a favorable agreement with potential developers of the new 
technology.  The university and state will profit by the creation of a 
revenue stream that can be put to creative uses in research and 
scholarship or general enhancement of the university mission. The 
developer profits, thus creating new jobs at the research, sales and 
manufacturing levels.  And finally, as part of the negotiations for rights to 
the technology, leverage can be put on the developer for some or all of the 
technology to be developed locally, thus creating jobs in the geographical 
area. 
 
 There are some negatives to patenting.  The cost of filing and 
defending a worldwide patent could easily rise above $125,000, with 
additional annual maintenance fees required. This is above and beyond 
the cost of the research itself, which in the case of many technologies can 
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be very high.  Such costs are not trivial, thus discouraging universities and 
inventors unless they have a sure winner.  And when can you be certain 
that you have a sure winner? 
 
 Delaying publication until patents are filed conflicts with one of the 
principle aims of academic institutions, which is the sharing of new 
knowledge in a timely manner.  Pressure to publish from the tenure and 
promotion standpoint and excitement about the discovery of new 
knowledge often lead faculty inventors to share their findings immediately 
rather than waiting to file patents or copyrights. The inventor may gain in 
prestige through early publication, but society loses when promising new 
technology is never developed because it is not protected prior to 
publication.  How would you feel if you knew that someone discovered a 
potential cure for cancer or AIDS, but it could not benefit society because 
lack of patent protection made it too economically risky to develop?” 
 
 As more of us are asked to balance basic with applied research we 
need to be aware of the need to protect our intellectual property in a timely 
manner.  Universities must continue to find ways to support the protection 
of intellectual property while not losing sight of their greater goal of 
generating and disseminating new knowledge. 
